FROM:
Description
e-therapeutics plc (“ETX”) combines computation and RNAi to discover and develop life-transforming medicines. The computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. The Company is progressing a pipeline of highly differentiated RNAi therapies across a variety of therapeutic areas with high unmet need.
READ MORE >
Company Snapshot
Status
Live
Price
9.50
Ticker
ETX
Class
ORD
Settlement
CREST
Industry
Professional, scientific & technical services
COUNTRY
United Kingdom
Company Number
04304473
ISIN
GB00B2823H99
Currency
GBX
COMPANY INSIGHTS
Incorporated
04304473
Shares in Issue
584,335,487
Market Cap
£56.39m
key features of trading on jp jenkins
BUYERS
Buyers decide on the price per share they’re willing to pay, and the number of shares they wish to buy.
SELLERS
Sellers decide the minimum price they’ll accept for their shares.
IMPORTANT INFORMATION
e-therapeutics plc is an unlisted company and shares in e-therapeutics plc are not traded on an investment exchange such as the London Stock Exchange or the Alternative Investment Market. This means share transactions can be infrequent, and there may be a delay between you giving instructions to buy or sell shares and your order being completed. It also means it can be difficult to assess your investment’s value.
Description
e-therapeutics plc (“ETX”) combines computation and RNAi to discover and develop life-transforming medicines. The computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. The Company is progressing a pipeline of highly differentiated RNAi therapies across a variety of therapeutic areas with high unmet need.
READ MORE >
Latest News
SEE MORE NEWS ARTICLES >
e-therapeutics plc Management Information
Ali Mortazavi
CEO
Professor Trevor Jones CBE
Independent Non-Executive Chairman
Michael Bretherton
Independent Non-Executive Director
Alan Whitmore
Chief Scientific Officer
Laura Roco-Alonso, PHD
Chief Operating and Business Officer
Timothy Bretherton
Chief Financial Officer
e-therapeutics plc Contact Details
Address
4 Kingdom Street,
London,
England,
W2 6BD
London,
England,
W2 6BD
EMAIL
contact@etherapeutics.co.uk
phone
+44 (0) 20 4551 8888
Contacts
Registrars
Neville Registrars Limited
Neville House
18 Laurel Lane
Halesowen
West Midlands
B63 3DA
www.nevilleregistrars.co.uk
Neville House
18 Laurel Lane
Halesowen
West Midlands
B63 3DA
www.nevilleregistrars.co.uk
+44 (0) 121 585 1131
TRANSACTING ON JP JENKINS
‘Trading‘ on JP Jenkins is done via a matched bargain facility, this means that on instruction from your ‘Broker’ we will endeavour to match your shares against other buyer(s) or seller(s) who are also looking to transact. Requests to trade are performed on an availability basis, should an instruction be cancelled, altered or amended in anyway by an instruction from your broker then it shall lose its active place in the queue and reset to the end of list. JP Jenkins receives orders from brokers electronically via a FIX message or should your broker not have a FIX connection to our platform via telephone. If you do not have a UK registered stockbroker you will find a list of brokers that we have worked with to download here. You will also find a list of UK brokers at the bottom of this page and their contact details should you need to appoint one. JP Jenkins can ONLY take instruction to transact from a UK-registered stockbroker and cannot offer investment advice into companies displayed on our website. If you are unsure about trading please consult a financial advisor or wealth manager to assist you in determining what is right for you
